Navigating the Oncology Frontier with Harpoon Therapeutics Acquisition In a significant strategic move, pharmaceutical giant Merck & Co. ( NYSE:MRK ) has announced its plans to acquire cancer drugmaker Harpoon Therapeutics Inc. ( NASDAQ:HARP ) in a transformative deal valued at $680 million. The move aims to solidify Merck's leadership position in the highly...
Hi, according to my analysis of mrk stock. The stock looks negative. The stock broke the bottom at the 106 level. It also broke the ascending channel to the upside, as shown in the analysis. These are all indications that the stock is still under pressure from sellers. good luck for everbody
Merck and Company (MRK) is trading within a Channel Down since the May 03 High. Even though the price didn't touch the bottom (Lower Lows trend-line) of the Channel Down, having completed 4 straight green 1D candles indicates that most likely we have seen the new low of this sequence. Assuming the current bullish wave will make at least a +7.10% extension like the...
The pool-season is about to start, and Merck has already secured its place on the water slide, which should take it further downwards below the support at $110.66. However, there is still a 35% chance that the share might catch a bubbling fountain which could push it above the resistance at $119.65. In that case, we would expect Merck to develop a new top in the...
NASDAQ:AZN trading at an area of value. Looking forward to a breakout on the upside. NYSE:MRK has done well so far, need more healthcare stocks to catchup.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive...
Divergent on the downside across multiple timeframes. Betting on a triangle B formation, now due for a C Wave to the upside. No confirmation yet. Speculating that this might be a very short term event. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in...
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. The company does business as Merck Sharp & Dohme outside the United States and Canada. Merck was able to break the support lines. For now, it completed its pullback to support...
Merck and Company Short Term We look to Sell at 93.34 (stop at 96.33) We look to sell rallies. Price action looks to be forming a top. Although the bulls are in control, the stalling positive momentum indicates a turnaround is possible. There is scope for mild buying at the open but gains should be limited. Our profit targets will be 86.55 and 83.96...
One more huge pharma firm that is biting the dust. A giant flat with a C wave confirmed. No way but down on this one. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted,...
Merck & Company, Inc. ( NYSE:MRK ) Sector: Health Technology (Pharmaceuticals: Major) Market Capitalization: $213.987B Current Price: $84.62 Breakout price: $91.40 Buy Zone (Top/Bottom Range): $83.60-$79.90 Price Target: $103.20-$105.80 Estimated Duration to Target: 672-696d Contract of Interest: $MRK 1/19/24 85c Trade price as of publish date: $10.17/contract
After a correction, I expect that now a strong upward movement will follow.
Immediate targets 85, 86. Invalidation at 76. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels...
And that's expected to an extent after a sizeable and quick drop. Merck did one, and fractally we are due to a rise that can potentially be viable percentage wise. But who knows what will happen. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with...
Several DCF valuations have suggested that the current price is on average +35% under the fair price. I took a quick look at their financials : their income last 5 years is positive, their revenue have grown last 5 years, their current asset > current liabilities and their Free Cash Flow can deal with their debts (i.e if they decided to pay off all of that...
MRK bounced off resistance yesterday. It also formed On Balance Volume divergence. I am bullish on Merck stock.
Rising Wedge and Ascending H&S, leading to a break down over a weak uptrend line down to the .618 Fibonacci line Rising wedges and H&S patterns are both considered bearish Attaching my thoughts about the ascending H&S
Pfizer is now outperforming Merck and Moderna stocks after announcing its anti-COVID pill despite its shares not being the best option for investments in the first half of this year. Pfizer stocks gained only 35% since the beginning of this year until mid-August. Moderna stocks were skyrocketed by 375% for the same period. So, undoubtedly Moderna was the...